Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

We Can Medicines Co., Ltd. (6929.TWO)

34.95
+2.35
+(7.21%)
At close: April 30 at 1:30:37 PM GMT+8
Loading Chart for 6929.TWO
  • Previous Close 32.60
  • Open 32.55
  • Bid 34.60 x --
  • Ask 34.95 x --
  • Day's Range 32.55 - 35.55
  • 52 Week Range 30.15 - 74.20
  • Volume 27,382
  • Avg. Volume 20,139
  • Market Cap (intraday) 1.568B
  • Beta (5Y Monthly) -0.47
  • PE Ratio (TTM) --
  • EPS (TTM) -1.09
  • Earnings Date --
  • Forward Dividend & Yield 0.27 (0.78%)
  • Ex-Dividend Date Aug 1, 2024
  • 1y Target Est --

We Can Medicines Co., Ltd. operates a chain of drug stores in Taiwan. The company offers medicine, health food, maternal and infant product, beauty care products, and medical equipment. It sells its products through retail stores and online under the VITALPLUS and Sapporo brands. The company was formerly known as Shenglin Pharmaceutical Co., Ltd. The company was founded in 1972 and is headquartered in Taichung, Taiwan. We Can Medicines Co., Ltd. operates as a subsidiary of Yousheng Medical Technology Co., Ltd.

www.yourchance.com.tw

1,005

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6929.TWO

View More

Performance Overview: 6929.TWO

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6929.TWO
9.57%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
12.16%

1-Year Return

6929.TWO
51.26%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.79%

3-Year Return

6929.TWO
17.96%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
21.96%

5-Year Return

6929.TWO
17.96%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
84.09%

Compare To: 6929.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6929.TWO

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    1.57B

  • Enterprise Value

    2.50B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.46

  • Price/Book (mrq)

    1.40

  • Enterprise Value/Revenue

    0.77

  • Enterprise Value/EBITDA

    8.69

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.44%

  • Return on Assets (ttm)

    -1.05%

  • Return on Equity (ttm)

    -4.88%

  • Revenue (ttm)

    3.27B

  • Net Income Avi to Common (ttm)

    -47.18M

  • Diluted EPS (ttm)

    -1.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    305.67M

  • Total Debt/Equity (mrq)

    111.21%

  • Levered Free Cash Flow (ttm)

    156.69M

Research Analysis: 6929.TWO

View More

Company Insights: 6929.TWO

Research Reports: 6929.TWO

View More